Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma

NCT07615049 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT07615049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07615049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Recruiting
Start date
December 2, 2026
Completion date
April 30, 2030
Enrollment
296 (estimated)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent soft tissue sarcoma of the trunk and extremities, resectable soft tissue sarcoma of the trunk and extremities, soft tissue sarcoma of the trunk and extremities, stage ii soft tissue sarcoma of the trunk and extremities ajcc v8, stage iii soft tissue sarcoma of the trunk and extremities ajcc v8